Literature DB >> 20428040

Synthesis and antimicrobial activity of new 4-heteroarylamino coumarin derivatives containing nitrogen and sulfur as heteroatoms.

Biljana R Dekić1, Niko S Radulović, Vidoslav S Dekić, Rastko D Vukićević, Radosav M Palić.   

Abstract

Synthesis, spectral analysis and bioactivity of new coumarin derivatives are described in this paper. Eight new coumarin derivatives were synthesized in moderate to good yields by condensation of 4-chloro-3-nitrocoumarin and the corresponding heteroarylamine. The synthesized compounds were tested for their in vitro antimicrobial activity, in a standard disk diffusion assay, against thirteen strains of bacteria and three fungal strains. They have shown a wide range of activity - from one completely inactive compound to medium active ones.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20428040      PMCID: PMC6257190          DOI: 10.3390/molecules15042246

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.411


1. Introduction

Coumarin derivatives have been shown to possess a remarkably broad spectrum of biological activity including antibacterial [1,2], antifungal [3,4,5], anticoagulant [6], anti-inflammatory [7], antitumor [8,9] and anti-HIV [10] activity. In addition, these compounds are used as additives in food and cosmetics [11], dispersed fluorescent brightening agents and as dyes for tuning lasers [12]. Main representatives of the class are the hydroxyl derivatives, 4- and 7-hydroxycoumarins, also biologically active and very important for the synthesis of other coumarin derivatives. On the other hand, the nitrogen and sulfur heterocyclic system families are very interesting due to their physicochemical properties, especially in the sense of design of new drugs and new materials. The chemistry and pharmacology of thiazole derivatives has been of great interest to medicinal chemists lately [13]. The pyrazole ring is a prominent structural moiety found in numerous pharmacologically active compounds. Pyrazole-based derivatives have been regarded as anxiolytics [14], GABA receptor antagonists and insecticides [15], potential PET ligands for CB1 receptors [16], anti-inflammatory, antimicrobial [17], and growth inhibition agents [18]. In continuation of our ongoing interest in synthesis of the new coumarin derivatives [20,21,22,23,24], and having in mind the above considerations, we have been prompted to synthesize new, possibly more potent, pharmacologically active compounds. We decided to combine the coumarinic system with the above named groups of compounds in hope that the resulting novel heterocycles would be biologically active. Additionally, a recent QSAR study of the antimicrobial activity of some 3-nitrocoumarins has put forward some new arguments in this direction [19]. In connection with our previous work [20,21,22,23,24], in the present paper we report on the synthesis of novel 4-heteroarylamino-3-nitrocoumarin derivatives and the screening of their in vitro antimicrobial activity.

2. Results and Discussion

The investigations have been started by synthesis of 4-chloro-3-nitrocoumarin (3) applying the known procedure [24], which was, then, submitted to the reaction with the corresponding nucleophiles 4a–h, all being commercially available [4,5-dihydro-1,3-thiazol-2-amine (4a), 5-methyl-1,3-thiazol-2-amine (4b), 4-methyl-1,3-thiazol-2-amine (4c), 4H-1,2,4-triazol-4-amine (4d), 4-amino-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one (4e), 5,6-dimethyl-1,3-benzothiazol-2-amine (4f), 1H-benz-imidazol-2-amine (4g) and 1H-indazol-6-amine (4h)]. The reaction has been performed by refluxing the substrate 3, the corresponding nucleophile 4a–h and triethylamine in a 1:1:2 ratio (Scheme 1).
Scheme 1

Synthesis of 4-heteroarylamino-3-nitrocoumarin derivatives 5a–h.

Synthesis of 4-heteroarylamino-3-nitrocoumarin derivatives 5a–h. The target 4-heteroarylamino-3-nitrocoumarin derivatives 5a–h were obtained in medium to good yields (66–89%), as it can be seen in Table 1.
Table 1

Characterization data of 4-heteroarylamino-3-nitrocoumarin derivatives 5a–h.

CompoundArFormulaMp/ oCColourYield/ %
5aC12H9N3O4S218-220yellow75
5bC13H9N3O4S229-232orange71
5cC13H9N3O4S212-215yellow72
5dC11H7N5O4249-252yellow82
5eC20H16N4O5240-242yellow89
5fC18H13N3O4S240-242yellow66
5gC16H10N4O4253-255yellow76
5hC16H10N4O4255-257yellow69
Characterization data of 4-heteroarylamino-3-nitrocoumarin derivatives 5a–h. The structures of compounds 5a–h were confirmed using IR and NMR spectroscopy, and HRMS. The IR spectra of synthesized compounds showed N-H and Ar-H absorptions in the range of 3,040 to 3,391 cm-1 and strong bands at 1,656–1,722 cm-1 corresponding to absorptions of the C=O and/or C=N bonds. The IR absorptions due to the presence of the 3-NO2 group appeared at 1,319–1,382 and 1,523–1,556 cm-1. In 1H-NMR spectra, aromatic protons of the coumarin moiety resonated at 7.25–8.45 ppm. The H-6 and H-8 protons were more shielded and appeared as multiplets at 7.25–7.60 ppm. In the case of compound 5g, H-8 proton signal overlapped with the H-5’ and H-6’ signals of the aryl side group. Protons H-5 and H-7 were more downfield and appeared as doublets of doublets at 8.06–8.45 and doublets of triplets at 7.57–7.95 ppm, respectively. In 1H-NMR spectrum of compound 5h, thesignal of H-7 overlapped with the resonance of H-4’, while the signal of the proton H-5 in the spectrum of compound 5f overlapped with the signals of the other aromatic protons of the coumarin moiety and aryl side group of the molecule. The synthesized compounds 5a–h were screened for their in vitro antimicrobial activity against thirteen strains of bacteria and three fungi strains using a disk diffusion assay [20,25]. The compounds were tested at the dose of 500 μg per disk [50mL of the samples solutions (10 mg/mL) in DMSO]. Measured susceptibility zones to the nearest mm were the clear zones around the disk inhibiting the microbial growth. The obtained results are listed in Table 2. As it can be seen, the prepared compounds possess a wide range of activities - from a completely inactive compound 5e to medium active ones. The synthesized compounds 5a–h showed no special selectivity towards any particular microorganism, although the bacterial strains showed greater susceptibility. Also, the activity of the synthesized compounds was slightly higher against Gram-positive compared to Gram-negative bacteria. The largest inhibition zones were noted for S. aureus and S. lutea. On the other hand, the most resistant strain was S. cerevisiae, being almost completely unsusceptible to the tested compounds. Considering the antimicrobial effect towards the different strains of the same microorganism, in the case of E. coli ATCC 8739 and E. coli ATCC 25922, the latter was less resistant to all compounds. Two different strains of P. aeruginosa exhibited similar susceptibility to the tested compounds. The most active compounds were 5c, 5g and 5h, showing reduction of bacterial and fungal growth comparable with the one exhibited by the standards used as positive control (tetracycline and nystatine), especially against medically important pathogens, though in a much larger dose. The lack of susceptibility of all tested microorganisms toward 5e was probably the consequence of sterically-hindered nitrogen atoms of the pyrazole ring.
Table 2

The antimicrobial activity - diameters of growth inhibition zonesof compounds 5a–h in a disk diffusion assay at a dose of 500 μg per disk.

Microorganism compound
5a5b5c5d5e5f5g5hTetracyclineNystatine
B. subtilis 20172016na16191927nt
Cl. pyogenes 19212117na20202027nt
Enterococcus sp. 18192217na20202128nt
M. flavus 18192217na17182031nt
S. lutea 20222418na17232227nt
S. aureus 20202718na19232025nt
E. coli ATCC 8739 18162015na18152027nt
E. coli ATCC 25922 18182418na20182028nt
K. pneumoniae 14121413na1415na23nt
S. enteritidis 19162218na20121726nt
P. vulgaris 20182017na18182026nt
P. aeruginosa ATCC 27857 17192117na18172126nt
P. aeruginosa ATCC 9027 19172217na19181525nt
A. niger 12141814na1315nant18
C. albicans 14141515na141515nt19
S. cerevisiae nana1010na14nanant17
The antimicrobial activity - diameters of growth inhibition zonesof compounds 5a–h in a disk diffusion assay at a dose of 500 μg per disk. In order to make the discussion more easy to follow and the conclusions statistically supported, we performed agglomerative hierarchical clustering (AHC) on the mentioned samples (Table 2), using the Excel program plug-in XLSTAT version 2008.6.07. The method was applied utilizing the values of diameters of growth inhibition zones as original variables without any recalculation. The results of AHC are presented in Figure 1. AHC was performed using Pearson dissimilarity (as aggregation criteria simple linkage, unweighted pair-group average and complete linkage were used) and Euclidean distance (aggregation criterion: weighted pair-group average, unweighted pair-group average and Ward’s method). The definition of the groups was based on Pearson correlation, using complete linkage and unweighted pair-group average method. AHC analysis has clearly indicated the existence of four groups of compounds under study (designations of the compounds were given in Scheme 1).
Figure 1

Dendrogram (AHC analysis) representing antimicrobial activity (variables-diameters of growth inhibition zones) dissimilarity relationships of the synthesized compounds (observations) obtained by Euclidian distance dissimilarity (dissimilarity within the interval [0, 400]), using aggregation criterion-Ward’s method. Four groups of the compounds were found.

Dendrogram (AHC analysis) representing antimicrobial activity (variables-diameters of growth inhibition zones) dissimilarity relationships of the synthesized compounds (observations) obtained by Euclidian distance dissimilarity (dissimilarity within the interval [0, 400]), using aggregation criterion-Ward’s method. Four groups of the compounds were found. Compound 5e showed no activity at all towards the tested microorganisms, and was not included in the AHC analysis. A single compound from the first group, 5h, is distinguished from the rest of the compounds. Structurally speaking, in 5h the indazole substituent was connected to the coumarin moiety in such a way that the larger distance of the indazole nitrogen atoms from the nitro-group of coumarin moiety might be responsible for the observed activity. No correlation between the structure of the compounds and the observed antimicrobial activity can be drawn out for the compounds placed in the three remaining groups. The marked antimicrobial activity of the synthesized compounds makes the 4-arylamino-3-nitrocoumarin derivatives, with the nitrogen and sulfur as heteroatoms, interesting for further investigation and shows that they are a good basis for the synthesis of new, potentially more physiologically active compounds.

3. Experimental Section

3.1. General

Melting points were determined on a Kofler hot-plate apparatus and are uncorrected. HRMS(EI) spectra were recorded on a Finnigan-MAT 8230 BE mass spectrometer. The IR measurements (ATR- attenuated total reflectance) were carried out with a Thermo Nicolet model 6700 FTIR instrument. The NMR spectra were recorded on a Varian Gemini 200 spectrometer(1H-NMR at 200 MHz, 13C-NMR at 50 MHz), using DMSO-d6 as the solvent. Chemical shifts are expressed in δ (ppm) using TMS (Me4Si) as the internal standard. For TLC, silica gel plates (Kiesel 60 F254, Merck) were used. Visualization was affected by spraying the plates with 1:1 aqueous sulfuric acid and then heating. All the reagents and solvents were obtained from commercial sources (Aldrich, USA; Merck, Germany; Fluka, Germany) and used as received, except that the solvents were purified by distillation.

3.2. Synthesis of 4-chloro-3-nitrocoumarin

According to the previously published procedure [26], 4-hydroxycoumarin (1) was nitrated in glacial AcOH with 72% HNO3 to afford 4-hydroxy-3-nitrocoumarin (2). Starting compound 3 was prepared from 4-hydroxy-3-nitrocoumarin (2) following the method of Kaljaj et al. [27]. The preparation was carried out in the following manner: N,N-dimethylformamide (DMF, 2 mL, 26 mmol) was cooled to 10 °C in an ice bath. With stirring, POCl3 (4 g, 26 mmol) was added dropwise, and the obtained mixture was stirred for an additional 15 min. Then, the ice bath was removed and the reaction was left to proceed at room temperature for a further 15 min. Finally, the solution of 4-hydroxy-3-nitrocoumarin (2, 5.4 g; 26 mmol) in DMF (12.5 mL) was added dropwise. After 15 minutes of stirring, the reaction was stopped by adding cold water (15 mL). The precipitated solid was collected by filtration and washed with saturated sodium-bicarbonate solution and water. Recrystallisation from the mixture of benzene-hexane (1:1 volume ratio) yielded yellow crystals of 3 (5.1 g; 22.6 mmol) in 87% yield, mp 162–163 °C. The procedure was repeated twice.

3.3. General procedure for the synthesis of 4-heteroarylamino-3-nitrocoumarins

A solution of 4-chloro-3-nitrocoumarin (3, 1 g, 4.4 mmol) and the appropriate heteroarylamine 4a–h (4.4 mmol) in ethyl acetate (10 mL) was refluxed in the presence of triethylamine (1 mL, 7.2 mmol) for 3–6 h. After cooling, the precipitated solid was filtered off, washed with ethyl acetate and water. The purity of the synthesized compounds was checked by TLC. 4-(4,5-dihydro-1,3-thiazol-2-ylamino)-3-nitro-2H-chromen-2-one (5a): IR (neat): 3,350 – 3,083 (N-H and Ar-H), 2,945, 1,680 (C=O), 1,605 (C=N), 1,560 (C=C), 1,523 and 1,322 (NO2), 1,219, 1,073, 917, 899, 749 cm−1; 1H=NMR (DMSO-d6) δ ppm: 8.29 (dd, 1H, H-5, J = 1.6, 8.3 Hz), 7.75, (dt, 1H, H-7, J = 1.4, 8.6 Hz), 7.40–7.54 (m, 2H, H-6, H-8), 3.43-3.55 (overlapping signals, 4H; H-4’, H-5’); 13C- NMR (DMSO-d6) δ ppm: 155.4, 151.1, 147.2, 134.3, 124.8, 124.4, 117.8, 116.5, 114.1, 112.8, 44.5, 32.5; HRMS(EI): M+ (C12H9N3O4S), 291.2810; requires 291.2826 (Δ = -1.6 mmu). 4-[(5-methyl-1,3-thiazol-2-yl)amino]-3-nitro-2H-chromen-2-one (5b): IR (neat): 3,367–3,116 (N-H and Ar-H), 2,977 (C-H), 1,682 (C=O), 1,648 (C=N), 1,583 (C=C), 1,523 and 1,382 (NO2), 1,204, 1,073, 860, 789 cm−1; 1H-NMR (DMSO-d6) δ ppm: 8.06 (dd, 1H, H-5, J = 1.4, 8.0 Hz), 7.71 (dt, 1H, H-7, J = 1.7, 8.4 Hz), 7.34–7.43 (m, 2H, H-6, H-8), 7.14 (brs, 1H, H-4’), 2.25 (s, 3H, CH3); 13C-NMR (DMSO-d6) δ ppm: 155.4, 152.2, 152.1, 134.3 (two C), 126.4, 124.7, 122.7, 122.6, 119.6, 117.8, 117.0, 12.5; HRMS(EI): M+ (C13H9N3O4S), 303.2951; requires 303.2933 (Δ = +1.8 mmu). 4-[(4-methyl-1,3-thiazol-2-yl)amino]-3-nitro-2H-chromen-2-one (5c): IR (neat): 3,385–3,175 (N-H and Ar-H), 2,978, 2,945 (C-.H), 1,677 (C=O), 1,599 (C=N), 1,552 (C=C), 1,513 and 1,319 (NO2), 1,273, 1,036, 803, 756 cm−1; 1H-NMR (DMSO-d6) δ ppm: 8.06 (d, 1H, H-5, J = 7.4 Hz), 7.72 (dt, 1H, H-7, J = 1.7, 8.4 Hz), 7.35–7.44 (m, 2H; H-6, H-8), 6.62 (s, 1H, H-5’), 2.17 (s, 3H, CH3); 13C-NMR (DMSO-d6) δ ppm: 155.5, 155.4, 152.2, 152.1, 134.3, 126.4, 126.3, 124.7, 119.9, 117.8, 117.0, 103.7, 14.0; HRMS(EI): M+ (C13H9N3O4S) 303.2919; requires 303.2933 (Δ = -1.4 mmu). 3-nitro-4-(4H-1,2,4-triazol-4-ylamino)-2H-chromen-2-one (5d): IR (neat): 3,391–3,101 (N-H and Ar-H), 2,942, 1,656 (C=O), 1,612 (C=N), 1,595 (C=C), 1,527 and 1,332 (NO2), 1,292, 1,034, 929, 798 cm−1; 1H-NMR (DMSO-d6) δ ppm: 8.85 (s, 2H, H-3’, H-5’), 8.20 (dd, 1H, H-5, J = 1.8, 8.1 Hz), 7.62 (dt, 1H, H-7, J = 1.5, 8.7 Hz), 7.25-7.38 (m, 2H, H-6, H-8), 2.50 (s, 1H, N-H); 13C-NMR (DMSO-d6) δ ppm: 155.9, 154.2, 151.2, 140.9 (two C), 132.9, 124.8, 124.1, 118.3, 116.8, 112.4; HRMS(EI): M+ (C11H7N5O4), 273.2051; requires 273.2044 (Δ = +0.7 mmu). 1,5-dimethyl-4-[(3-nitro-2-oxo-2H-chromen-4-yl)amino]-2-phenyl-1,2-dihydro-3H-pyrazol-3-one (5e): IR (neat): 3,205 – 3,065 (N-H and Ar-H), 2,920 (C-H), 1,706 (C=O), 1,650 (C=N), 1,611 (C=C), 1,556 and 1,370 (NO2), 1,284, 1,056, 895, 794 cm−1; 1H-NMR (DMSO-d6) δ ppm: 9.56 (s, 1H, N-H), 8.39 (d, 1H, H-5, J = 8.0 Hz), 7.79 (t, 1H, H-7, J = 8.0 Hz), 7.27–7.60 (m, 7H, H-6, H-8, H-2”, H-3”, H-4”, H-5”, H-6”), 3.11 (s, 3H, CH3-N-1’), 2.20 (s, 3H, CH3-C-5’); 13C-NMR (DMSO-d6) δ ppm: 161.0, 155.5, 153.1, 151.2, 146.2, 134.8, 134.3, 129.5, 129.4 (two C), 127.3, 125.1, 124.8 (two C), 124.4, 117.7, 113.9, 105.7, 35.5, 10.5; HRMS(EI): M+ (C20H16N4O5), 392.3662; requires 392.3648 (Δ = +1.4 mmu). (5e): IR (neat): 3,205 – 3,065 (N-H and Ar-H), 2,920 (C-H), 1,706 (C=O), 1,650 (C=N), 1,611 (C=C), 1,556 and 1,370 (NO2), 1,284, 1,056, 895, 794 cm−1; 1H-NMR (DMSO-d6) δ ppm: 9.56 (s, 1H, N-H), 8.39 (d, 1H, H-5, J = 8.0 Hz), 7.79 (t, 1H, H-7, J = 8.0 Hz), 7.27–7.60 (m, 7H, H-6, H-8, H-2”, H-3”, H-4”, H-5”, H-6”), 3.11 (s, 3H, CH3-N-1’), 2.20 (s, 3H, CH3-C-5’); 13C-NMR (DMSO-d6) δ ppm: 161.0, 155.5, 153.1, 151.2, 146.2, 134.8, 134.3, 129.5, 129.4 (two C), 127.3, 125.1, 124.8 (two C), 124.4, 117.7, 113.9, 105.7, 35.5, 10.5; HRMS(EI): M+ (C20H16N4O5), 392.3662; requires 392.3648 (Δ = +1.4 mmu). 4-[(5,6-dimethyl-1,3-benzothiazol-2-yl)amino]-3-nitro-2H-chromen-2-one (5f): IR (neat): 3,298–3,040 (N-H and Ar-H), 2,935 (C-H), 1,722 (C=O), 1,641 (C=N), 1,600 (C=C), 1,548 and 1,371 (NO2), 1,279, 1,061, 869, 755 cm−1; 1H-NMR (DMSO-d6) δ ppm: 7.95 (dt, 1H, H-7, J = 1.7 Hz, 8.0 Hz), 7.42–7.81 (m, 5H, H-5, H-6, H-8, H-4’, H-7’), 7.36 (s, 1H, N-H), 2.19 (overlapping signals, 6H, 2CH3); 13C- NMR (DMSO-d6) δ ppm: 154.3, 153.3, 152.8, 152.5, 140.6, 137.0, 136.5, 135.2, 134.1, 126.4, 125.5, 124.0, 119.0, 117.6, 114.1, 113.2, 19.6, 19.3; HRMS(EI): M+ (C18H13N3O4S) 367.3779, requires 367.3785 (Δ = -0.6 mmu). 4-(1H-benzimidazol-2-ylamino)-3-nitro-2H-chromen-2-one (5g): IR (neat): 3,125–3,042 (N-H and Ar-H), 2,979, 1,687 (C=O), 1,610 (C=N), 1,573 (C=C), 1,542 and 1,360 (NO2), 1,279, 1,075, 804, 756 cm−1; 1H-NMR (DMSO-d6) δ ppm: 8.33 (dd, 1H, H-5, J = 1.6 Hz, 7.9 Hz), 7.57 (dt, 1H, H-7, J = 1.7 Hz, 8.2 Hz), 7.37 (dt, 1H, H-6, J = 1.2 Hz, 8.5 Hz), 7.15-7.29 (m, 3H, H-8, H-5’, H-6’), 6.81–7.06 (m, 2H, H-4’, H-7’); 13C-NMR (DMSO-d6) δ ppm: 158.5, 153.0, 150.1, 149.7, 131.4, 129.3, 129.1, 125.7, 124.7, 122.3 (two C), 116.1, 114.8 (two C), 105.7, 99.3; HRMS(EI): M+ (C16H10N4O4), 322.2741; requires 322.2750 (Δ = -0.9 mmu). 4-(1H-indazol-6-ylamino)-3-nitro-2H-chromen-2-one (5h): IR (neat): 3,373–3,075 (N-H and Ar-H), 1,687 (C=O), 1,605 (C=N), 1,590 (C=C), 1,538 and 1,344 (NO2), 1,240, 1,107, 876, 759 cm−1; 1H- NMR (DMSO-d6) δ ppm: 13.14 (brs, 1H, N-H), 10.42 (s, 1H, N-H), 8.45 (dd, 1H, H-5, J = 1.5 Hz, 7.3 Hz), 8.08 (s, 1H, H-3’), 7.70–7.84 (m, 2H, H-7, H-4’), 7.44–7.56 (m, 2H, H-6, H-8), 7.36 (d, 1H, H-7’, J = 0.8 Hz), 7.00 (dd, 1H, H-5’, J = 1.7, 8.5 Hz); 13C-NMR (DMSO-d6) δ ppm: 155.3, 151.7, 146.1, 139.6, 135.8, 134.5, 133.9, 124.8 (two C), 121.5, 121.2, 117.6, 117.1, 114.9, 114.8, 104.3; HRMS(EI): M+ (C16H10N4O4), 322.2739; requires 322.2750 (Δ = -1.1 mmu).

3.4. Antimicrobial activity

The in vitro antimicrobial activities of compounds 5a–hwere tested against a panel of laboratory control strains belonging to the American Type Culture Collection (Maryland, USA). Antibacterial activity was evaluated against six Gram-positive and seven Gram-negative bacteria. The Gram-positive bacteria used were: Bacillus subtilis (ATCC 6633), Clostridium pyogenes (ATCC 19404), Enterococcus sp. (ATCC 25212), Micrococcus flavus (ATCC 10240), Sarcina lutea (ATCC 9341) and Staphylococcus aureus (ATCC 6538). The Gram-negative bacteria utilized in the assays were: Klebsiella pneumoniae (ATCC 10031), Proteus vulgaris (ATCC 8427), Escherichia coli (ATCC 8739), Escherichia coli (ATCC 25922), Pseudomonas aeruginosa (ATCC 27857), Pseudomonas aeruginosa (ATCC 9027) and Salmonella enteritidis (ATCC 13076). The antifungal activity was tested against three organisms Aspergillus niger (ATCC 16404), Candida albicans (ATCC 10231) and Saccharomyces cerevisiae (ATCC 9763). A disk diffusion method, according to the NCCLS [25], was employed for the determination of antimicrobial activity of compounds 5a–h. The following nutritive media were used: Antibiotic Medium 1 (Difco Laboratories, Detroit, MI USA) for growing Gram-positive and Gram-negative bacteria, Tripton soy agar (TSA – Torlak, Belgrade) for C. albicans and A. niger, and Sabouraud dextrose agar (Torlak, Belgrade) for S. cerevisiae. Nutritive media were prepared according to the instructions of the manufacturer. All agar plates were prepared in 90 mm Petri dishes with 22 mL of agar, giving a final depth of 4 mm. One-hundred microliters of a suspension of the tested microorganisms (108 cells per mL) were spread on the solid media plates. Sterile filter paper disks (‘‘Antibiotica Test Blattchen”, Schleicher and Schuell, Dassel, Germany, 6 mm in diameter) were impregnated with 50 μL of the samples solutions (10 mg/mL) in DMSO (all solutions were filter-sterilized using a 0.45 μm membrane filter), i.e. 500 μg per disk, and placed on inoculated plates. These plates, after standing at 4 °C for 2 h, were incubated at 37 °C for 24 h for bacteria and at 30 °C for 48 h for the fungi. Standard disks of tetracycline and nystatine (origin – Institute of Immunology and Virology ‘‘Torlak”, 30 μg of the active component, diameter 6 mm) were used individually as positive controls, while the disks imbued with 50 μL of pure DMSO were used as a negative control. The diameters of the inhibition zones were measured in millimeters (to the nearest mm) using a ‘‘Fisher-Lilly Antibiotic Zone Reader” (Fisher Scientific Co., USA). Each test was performed in quintuplicate. In order to evaluate statistically any significant differences among mean values, a one-way ANOVA test was used. In all tests the significance level at which we evaluated critical values differences was 5%.

4. Conclusions

In summary, this paper describes the synthesis, spectral characterization and screening of antimicrobial activity of some new 4-arylamino-3-nitrocoumarin derivatives. 4-Chloro-3-nitro-coumarin proved to be a good electrophilic substrate in these reactions. The synthesized compounds showed a wide range of potentially promising antimicrobial activities. The notable antimicrobial effect of certain compounds confirms that these are a good basis for the production of a number of new, possibly physiologically active coumarin derivatives.
  10 in total

1.  Design, synthesis, computational and biological evaluation of new anxiolytics.

Authors:  Athina Geronikaki; Eugeni Babaev; John Dearden; Wim Dehaen; Dmitrii Filimonov; Irina Galaeva; Valentina Krajneva; Alexey Lagunin; Fliur Macaev; Guenadiy Molodavkin; Vladimir Poroikov; Serghei Pogrebnoi; Victor Saloutin; Alla Stepanchikova; Eugenia Stingaci; Natalia Tkach; Liudmila Vlad; Tatiana Voronina
Journal:  Bioorg Med Chem       Date:  2004-12-15       Impact factor: 3.641

2.  Antitumor activity of some coumarin derivatives.

Authors:  L D Raev; E Voinova; I C Ivanov; D Popov
Journal:  Pharmazie       Date:  1990-09       Impact factor: 1.267

3.  Synthesis and reactions of some new 4H-pyrano[3,2-c]benzopyran-5-one derivatives and their potential biological activities.

Authors:  R M Shaker
Journal:  Pharmazie       Date:  1996-03       Impact factor: 1.267

4.  Anti-AIDS agents. 37. Synthesis and structure-activity relationships of (3'R,4'R)-(+)-cis-khellactone derivatives as novel potent anti-HIV agents.

Authors:  L Xie; Y Takeuchi; L M Cosentino; K H Lee
Journal:  J Med Chem       Date:  1999-07-15       Impact factor: 7.446

5.  Synthesis and growth inhibition activity of alpha-bromoacrylic heterocyclic and benzoheterocyclic derivatives of distamycin A modified on the amidino moiety.

Authors:  Pier Giovanni Baraldi; Italo Beria; Paolo Cozzi; Nicoletta Bianchi; Roberto Gambari; Romeo Romagnoli
Journal:  Bioorg Med Chem       Date:  2003-03-20       Impact factor: 3.641

6.  Synthesis of [O-methyl-11C]1-(2-chlorophenyl)-5-(4-methoxyphenyl)-4-methyl-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide: a potential PET ligand for CB1 receptors.

Authors:  J S Dileep Kumar; Jaya Prabhakaran; Victoria Arango; Ramin V Parsey; Mark D Underwood; Norman R Simpson; Suham A Kassir; Vattoly J Majo; Ronald L Van Heertum; J John Mann
Journal:  Bioorg Med Chem Lett       Date:  2004-05-17       Impact factor: 2.823

7.  Synthesis, antibacterial and antifungal activity of 4-hydroxycoumarin derivatives, analogues of novobiocin.

Authors:  T Patonay; G Litkei; R Bognár; J Erdei; C Miszti
Journal:  Pharmazie       Date:  1984-02       Impact factor: 1.267

8.  QSAR study of antimicrobial activity of some 3-nitrocoumarins and related compounds.

Authors:  Zeljko Debeljak; Armin Skrbo; Ivona Jasprica; Ana Mornar; Vanda Plecko; Mihajlo Banjanac; Marica Medić-Sarić
Journal:  J Chem Inf Model       Date:  2007-05-10       Impact factor: 4.956

9.  Design, synthesis and biological evaluation of some pyrazole derivatives as anti-inflammatory-antimicrobial agents.

Authors:  Adnan A Bekhit; Tarek Abdel-Aziem
Journal:  Bioorg Med Chem       Date:  2004-04-15       Impact factor: 3.641

10.  GABA receptor antagonists and insecticides: common structural features of 4-alkyl-1-phenylpyrazoles and 4-alkyl-1-phenyltrioxabicyclooctanes.

Authors:  Robert E Sammelson; Pierluigi Caboni; Kathleen A Durkin; John E Casida
Journal:  Bioorg Med Chem       Date:  2004-06-15       Impact factor: 3.641

  10 in total
  8 in total

1.  Modulation of S. aureus and P. aeruginosa biofilm: an in vitro study with new coumarin derivatives.

Authors:  Tapas Das; Manash C Das; Antu Das; Sukhen Bhowmik; Padmani Sandhu; Yusuf Akhter; Surajit Bhattacharjee; Utpal Ch De
Journal:  World J Microbiol Biotechnol       Date:  2018-11-08       Impact factor: 3.312

2.  Synthesis Characterization and Biological Activities of Coordination Compounds of 4-Hydroxy-3-nitro-2H-chromen-2-one and Its Aminoethanoic Acid and Pyrrolidine-2-carboxylic Acid Mixed Ligand Complexes.

Authors:  Temitayo Aiyelabola; Ezekiel Akinkunmi; Efere Obuotor; Idowu Olawuni; David Isabirye; Johan Jordaan
Journal:  Bioinorg Chem Appl       Date:  2017-02-07       Impact factor: 7.778

3.  Effects of Coumarinyl Schiff Bases against Phytopathogenic Fungi, the Soil-Beneficial Bacteria and Entomopathogenic Nematodes: Deeper Insight into the Mechanism of Action.

Authors:  Vesna Rastija; Karolina Vrandečić; Jasenka Ćosić; Gabriella Kanižai Šarić; Ivana Majić; Dejan Agić; Domagoj Šubarić; Maja Karnaš; Drago Bešlo; Mario Komar; Maja Molnar
Journal:  Molecules       Date:  2022-03-28       Impact factor: 4.927

4.  Novel 4-substituted phenyl-2,2'-bichalcophenes and aza-analogs as antibacterial agents: a structural activity relationship.

Authors:  Warda A Hussin; Mohamed A Ismail; Wael M El-Sayed
Journal:  Drug Des Devel Ther       Date:  2013-03-22       Impact factor: 4.162

5.  A prodrug approach to the use of coumarins as potential therapeutics for superficial mycoses.

Authors:  Derry K Mercer; Jennifer Robertson; Kristine Wright; Lorna Miller; Shane Smith; Colin S Stewart; Deborah A O Neil
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240

6.  Synthesis and antibacterial activities of novel 4-hydroxy-7-hydroxy- and 3-carboxycoumarin derivatives.

Authors:  Pen-Yuan Lin; Kuang-Sheng Yeh; Chien-Ling Su; Shiow-Yunn Sheu; Tiffany Chen; Keng-Liang Ou; Mei-Hsiang Lin; Lin-Wen Lee
Journal:  Molecules       Date:  2012-09-10       Impact factor: 4.411

7.  Comparative Therapeutic Effects of Natural Compounds Against Saprolegnia spp. (Oomycota) and Amyloodinium ocellatum (Dinophyceae).

Authors:  Perla Tedesco; Paola Beraldo; Michela Massimo; Maria Letizia Fioravanti; Donatella Volpatti; Ron Dirks; Roberta Galuppi
Journal:  Front Vet Sci       Date:  2020-02-21

8.  Biological Activities Related to Plant Protection and Environmental Effects of Coumarin Derivatives: QSAR and Molecular Docking Studies.

Authors:  Vesna Rastija; Karolina Vrandečić; Jasenka Ćosić; Ivana Majić; Gabriella Kanižai Šarić; Dejan Agić; Maja Karnaš; Melita Lončarić; Maja Molnar
Journal:  Int J Mol Sci       Date:  2021-07-06       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.